Brief: Ipsen and U.S. peer Exicure: collaboration targeting rare neurodegenerative disorders

Exicure

02/08/2021 06:05

Aug 2 (Reuters) - Ipsen Sa  IPN.PA /Exicure  XCUR.O :
    * IPSEN AND EXICURE ENTER INTO EXCLUSIVE COLLABORATION
TARGETING
RARE NEURODEGENERATIVE DISORDERS
    * EXICURE WILL RECEIVE A $20M UPFRONT PAYMENT AND IS
ELIGIBLE TO
RECEIVE UP TO $1B IN OPTION EXERCISE FEES AND MILESTONE PAYMENTS
SHOULD IPSEN OPT INTO BOTH PROGRAMS, AS WELL AS TIERED
ROYALTIES, IN THIS DEAL
    * EXICURE WILL RECEIVE A $20M UPFRONT PAYMENT AND IS
ELIGIBLE TO
RECEIVE UP TO $1B IN OPTION EXERCISE FEES AND MILESTONE PAYMENTS
SHOULD IPSEN OPT INTO BOTH PROGRAMS, AS WELL AS TIERED ROYALTIES
    * IPSEN OBTAINS EXCLUSIVE OPTIONS TO SPHERICAL NUCLEIC ACIDS
(SNAS™) CURRENTLY UNDER DISCOVERY EVALUATION FOR HUNTINGTON'S
DISEASE AND ANGELMAN SYNDROME
    * EXICURE WILL BE RESPONSIBLE FOR DISCOVERY AND CERTAIN
PRE-CLINICAL DEVELOPMENT ACTIVITIES
    * IN EVENT IPSEN EXERCISES ITS OPTION TO TWO PROGRAMS, IPSEN
WILL
BE RESPONSIBLE FOR FURTHER DEVELOPMENT AND WORLDWIDE
COMMERCIALIZATION

Source text for Eikon:  ID:nBw4PTvQa 
Further company coverage:  IPN.PA 

 (Reporting by Sudip Kar-Gupta)
 ((sudip.kargupta@thomsonreuters.com;))